Baricitinib vs. hydroxychloroquine for cutaneous lichen planus: an assessor-blind randomized controlled trial
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llag210 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Hossein Kargar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Sulfonamides, Hydroxychloroquine, Azetidines, Pyrazoles. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Shiraz University of Medical Sciences, Arena Life Science company.
Abstract (Originalsprache)
Background
Lichen planus (LP) is a chronic autoimmune inflammatory disorder with limited effective long-term treatment options. Hydroxychloroquine has been widely used as systemic therapy, and although baricitinib, a Janus kinase 1/2 inhibitor, has shown promise in patients with refractory cases, comparative evidence is lacking.
Objectives
This study aimed to compare the efficacy and safety of baricitinib vs. hydroxychloroquine in patients with cutaneous LP.
Methods
In this randomized controlled trial, 32 patients with cutaneous LP were randomized to baricitinib 4 mg once daily or hydroxychloroquine 200 mg twice daily for 12 weeks. The primary outcome was the change in Lichen Planus Activity and Damage Index (LiPADI). Secondary outcomes included pruritus severity, patient satisfaction (each assessed using a 0–10 visual analogue scale) and Physician Global Assessment (PGA).
Results
Both groups showed significant improvement in pruritus severity and LiPADI scores (P < 0.001). Mean LiPADI scores decreased from 14.20 (SD 3.44) to 1.07 (SD 0.99) with baricitinib and from 12.18 (SD 3.28) to 5.27 (SD 2.28) with hydroxychloroquine (P = 0.03), indicating a greater reduction in disease activity with baricitinib. The pruritus visual analogue scale improved from 8.33 (SD 1.67) to 0.21 (SD 0.80) in the baricitinib group and from 8.81 (SD 1.66) to 3.27 (SD 1.01) in the hydroxychloroquine group (P < 0.001). Patient satisfaction increased from 4.46 (SD 0.83) to 8.78 (SD 1.12) and from 4.63 (SD 0.50) to 6.90 (SD 0.94), respectively (P = 0.001). PGA improved in both groups, but the between-group difference was not statistically significant (P = 0.38). No major or life-threatening adverse events were observed in both groups.
Conclusions
In this assessor-blinded randomized trial, both baricitinib and hydroxychloroquine improved cutaneous LP over 12 weeks. Baricitinib was associated with greater short-term improvement in disease activity and pruritus, along with higher patient satisfaction, without evidence of additional short-term safety concerns. The small sample size, short follow-up and nondouble-blind design warrant cautious interpretation. Large double-blind studies with longer follow-up are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
ORCID-Profile: Hossein Kargar, Mohammad Ali Esfandiari, Mehdi Ghahartars, Mohammad Mahdi Parvizi
Förderung
- Shiraz University of Medical Sciences
- Arena Life Science company
Zitieren
APA
Kargar, H., Esfandiari, M. A., Ghahartars, M., & Parvizi, M. M. (2026). Baricitinib vs. hydroxychloroquine for cutaneous lichen planus: an assessor-blind randomized controlled trial. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag210
Vancouver
Kargar H, Esfandiari MA, Ghahartars M, Parvizi MM. Baricitinib vs. hydroxychloroquine for cutaneous lichen planus: an assessor-blind randomized controlled trial. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag210
BibTeX
@article{Kargar2026,
author = {Kargar, Hossein and Esfandiari, Mohammad Ali and Ghahartars, Mehdi and Parvizi, Mohammad Mahdi},
title = {Baricitinib vs. hydroxychloroquine for cutaneous lichen planus: an assessor-blind randomized controlled trial},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag210}
}
EUVIMED